Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator-assigned therapy: A US-based study.
Bob G SchultzMichael BullanoDeepika ParataneKrithika RajagopalanPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2024)
This analysis suggests that Mean PPPY HCRU costs were 29%-64% lower with MBV versus other-AVTs.